RxDoctor Payments DataLook up a doctor →

Sanjeev Trehan, MD

Interventional Cardiology · Ogden, UTNPI 1750335907

Payments from drug & device makers

$94,864in general payments, 2019–2025

Across 755 payments — averaging $125.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$27K
  • Boston Scientific$26K
  • Shockwave Medical, Inc$6K
  • Edwards Lifesciences$6K
  • Silk Road Medical, Inc.$5K
  • Siemens Medical Solutions USA, Inc.$4K
  • plus $20K from 49 others

What the payments were for

  • Consulting fees$19,80021%
  • Speaking & faculty fees$31,38133%
  • Grants$550%
  • Travel & lodging$14,39215%
  • Food & beverage$29,10231%
  • Education$1340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,864 in reported general payments places this provider in the 80th percentile of 45 interventional cardiology providers in Utah.

See all interventional cardiology providers in Utah

Medicare billing

Part B allowed, 2024
$549,964
Medicare patients
1,152
Services billed
6,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban315$336,917
EntrestoSacubitril/Valsartan116$160,275
XareltoRivaroxaban149$140,859
Repatha SureclickEvolocumab74$63,438
FarxigaDapagliflozin Propanediol45$38,524
JardianceEmpagliflozin33$33,739
Praluent PenAlirocumab20$9,985
BrilintaTicagrelor14$9,951
Metoprolol Succinate347$4,963
VascepaIcosapent Ethyl12$4,285
Atorvastatin Calcium412$4,030
Ranolazine ErRanolazine24$3,938
Carvedilol295$3,461
ClopidogrelClopidogrel Bisulfate329$3,428
Bisoprolol Fumarate98$3,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$453$336,917315 claims
NovartisEntresto$582$160,275116 claims
Johnson & JohnsonXarelto$756$140,859149 claims
AstraZenecaFarxiga, Brilinta$194$48,47559 claims
Boehringer IngelheimJardiance$194$33,73933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 45 interventional cardiology providers in Utah.

Other interventional cardiology in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →